Biotie Therapies Oyj (BTH1V), the drugmaker that developed an anti-alcoholism medicine with H. Lundbeck A/S, has been approached by multiple potential partners for its experimental treatment for Alzheimer’s disease, Chief Executive Officer Timo Veromaa said. Through the acquisition of Synosia Therapeutics last year, Turku, Finland-based Biotie gained access to several drugs in development including SYN120, an Alzheimer’s medicine licensed from Roche Holding AG (ROG) in 2009. Roche has a one-time option to take back rights for SYN120 after evaluating data from an early- stage study to be released this quarter, Veromaa said in a telephone interview Feb. 16.
